Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis
Open accessAbstract
Background/Aims: Hepatic steatosis is caused by an imbalance between free fatty acids (FFAs) uptake, utilization, storage, and disposal.Understanding the molecular mechanisms involved in FFAs accumulation and its modulation could drive the development of potential therapies for Nonalcoholic fatty liver disease.The aim of the current study was to explore the effects of picroside II, a phytoactive found in Picrorhiza kurroa, on fatty acid accumulation vis-à-vis silibinin, a known hepatoprotective phytoactive from Silybum marianum.Methods: HepG2 cells were loaded with FFAs (oleic acid:palmitic acid/2:1) for 20 hours to mimic hepatic steatosis.The FFAs concentration achieving maximum fat accumulation and minimal cytotoxicity (500 μM) was standardized.HepG2 cells were exposed to the standardized FFAs concentration with and without picroside II pretreatment.Results: Picroside II pretreatment inhibited FFAs-induced lipid accumulation by attenuating the expression of fatty acid transport protein 5, sterol regulatory element binding protein 1 and stearoyl CoA desaturase.Preatreatment with picroside II was also found to decrease the expression of forkhead box protein O1 and phosphoenolpyruvate carboxykinase.Conclusions: These findings suggest that picroside II effectively attenuated fatty acid accumulation by decreasing FFAs uptake and lipogenesis.Picroside II also decreased the expression of gluconeogenic genes.(
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Picroside II effectively attenuated fatty acid accumulation in HepG2 cells via decreasing FFAs uptake and lipogenesis.
“Picroside II effectively attenuated the fatty acid accumulation in HepG2 cells via decreasing FFAs uptake and lipogenesis.”
From Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells (2021) · cites this paper as [18]
Picroside I did not show any effect on fatty acid accumulation in HepG2 cells.
“Picroside I on the other hand, did not show any effect on fatty acid accumulation in HepG2 cells.”
From Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells (2021) · cites this paper as [18]
The cell culture model of hepatic steatosis was established by loading HepG2 cells with FFAs mixture of OA:PA/2:1 as per the previous study.
“As per the previous study, the cell culture model of hepatic steatosis was established by loading HepG2 cells with FFAs mixture of OA: PA/2:1 [18].”
From Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells (2021) · cites this paper as [18]
Picroside II attenuates fatty acid accumulation in HepG2 cells by decreasing FFAs uptake and synthesis.
“Earlier, it was shown that picroside II significantly reduced fatty acid accumulation in HepG2 cells by decreasing the FFAs uptake and synthesis [18].”
From Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 2× · see citing works
“Besides hepatic FFAs uptake, increased lipogenesis is known to contribute towards TG accumulation in the hepatocytes via activation of transcription factor SREBP-1.”
BackgroundSunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672 · see citing works
Serviddio, G., Giudetti, A. M., Bellanti, F., Priore, P., Rollo, T., Tamborra, R., Siculella, L., Vendemiale, G., Altomare, E., & Gnoni, G. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024084 · Cited by 128 · see citing works
mRNA expression analysis by real-time PCR
Zanoni, I., & Ostuni, R. (2009) · Protocol Exchange · doi:10.1038/nprot.2009.138 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 28
- [1]Green CJ Hodson L The influence of dietary fat on liver fat accumulation Nutrients 2014 6 5018 5033 25389901 PMC4245577
- [2]Schaffer JE Lipotoxicity: when tissues overeat Curr Opin Lipidol 2003 14 281 287 12840659
- [3]Chalasani N Younossi Z Lavine JE Diehl AM Brunt EM Cusi K The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 2012 142 1592 1609 22656328
- [4]Sanyal AJ Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease Nat Clin Pract Gastroenterol Hepatol 2005 2 46 53 16265100
- [5]Rui L Energy metabolism in the liver Compr Physiol 2014 4 177 197 24692138 PMC4050641
- [6]Tolman KG Dalpiaz AS Treatment of non-alcoholic fatty liver disease Ther Clin Risk Manag 2007 3 1153 1163 18516264 PMC2387293
- [9]Antarkar DS Tathed PS Vaidya AB A pilot phase II trial with arogya-wardhani and Punarnavadi-Kwath in viral hepatitis Panminerva Med 1978 20 157 163 757281
- [10]Dwivedi Y Rastogi R Chander R Sharma SK Kapoor NK Garg NK Hepatoprotective activity of picroliv against carbon tetrachloride induced liver damage in rats Indian J Med Res 1990 92 195 200 2401541
- [12]Dwivedi Y Rastogi R Sharma SK Garg NK Dhawan BN Picroliv affords protection against thioacetamide-induced hepatic damage in rats Planta Med 1991 57 25 28 2062953
- [13]Visen PK Shukla B Patnaik GK Dhawan BN Prevention of galactosamine-induced hepatic damage by picroliv: study on bile flow and isolated hepatocytes (ex vivo) Planta Med 1993 59 37 41 8441780
- [14]Varghese L Agarwal C Tyagi A Singh RP Agarwal R Silibinin efficacy against human hepatocellular carcinoma Clin Cancer Res 2005 11 8441 8448 16322307
- [15]Cousin SP Hügl SR Wrede CE Kajio H Myers MG Jr Rhodes CJ Free fatty acid-induced inhibition of glucose and insulin-like growth factor 1-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1 Endocrinology 2000 142 229 240 11145586
- [17]Mahmood T Yang PC Western blot: technique, theory, and trouble shooting N Am J Med Sci 2012 4 429 434 23050259 PMC3456489
- [18]Malhi H Guicciardi ME Gores GJ Hepatocyte death: a clear and present danger Physiol Rev 2010 90 1165 1194 20664081 PMC2943859
- [19]Johnson NA Sachinwalla T Walton DW Smith K Armstrong A Thompson MW Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss Hepatology 2009 50 1105 1112 19637289
- [20]Catalano D Trovato GM Martines GF Randazzo M Tonzuso A Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study Liver Int 2008 28 1280 1287 18435716
- [21]Koutsari C Mundi MS Ali AH Patterson BW Jensen MD Systemic free fatty acid disposal into very low-density lipoprotein triglycerides Diabetes 2013 62 2386 2395 23434937 PMC3712051
- [22]Yan C Sun W Wang X Long J Liu X Feng Z Punicalagin attenuates palmitate-induced lipotoxicity in HepG2 cells by activating the Keap1-Nrf2 antioxidant defense system Mol Nutr Food Res 2016 60 1139 1149 26989875
- [24]Shetty SN Mengi S Vaidya R Vaidya AD A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease J Ayurveda Integr Med 2010 1 203 210 21547049 PMC3087357
- [25]Feldstein AE Canbay A Guicciardi ME Higuchi H Bronk SF Gores GJ Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice J Hepatol 2003 39 978 983 14642615
- [26]Gómez-Lechón MJ Donato MT Martínez-Romero A Jiménez N Castell JV O’Connor JE A human hepatocellular in vitro model to investigate steatosis Chem Bio Interact 2007 165 106 116 17188672
- [27]Pohl J Ring A Hermann T Stremmel W Role of FATP in parenchymal cell fatty acid uptake Biochim Biophys Acta 2004 1686 1 6 15522816
- [28]Mitsuyoshi H Yasui K Harano Y Endo M Tsuji K Minami M Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease Hepatol Res 2009 39 366 373 19054139
- [29]Doege H Grimm D Falcon A Tsang B Storm TA Xu H Silencing of hepatic fatty acid transporter protein 5 in vivo reverses dietinduced non-alcoholic fatty liver disease and improves hyperglycemia J Bio Chem 2008 283 22186 22192 18524776 PMC2494916
- [31]Pettinelli P Obregón AM Videla LA Molecular mechanisms of steatosis in nonalcoholic fatty liver disease Nutr Hosp 2011 26 441 450 21892559
- [33]Begriche K Massart J Robin MA Bonnet F Fromenty B Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease Hepatology 2013 58 1497 1507 23299992
- [35]Zhang W Patil S Chauhan B Guo S Powell DR Le J FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression J Biol Chem 2006 281 10105 10117 16492665
- [36]Salamone F Galvano F Cappello F Mangiameli A Barbagallo I Li Volti G Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis Transl Res 2012 159 477 486 22633099
Cited by
Sorted by citations
Intervention by picroside II on FFAs induced lipid accumulation and lipotoxicity in HepG2 cells
Dhami-Shah, H., Vaidya, R., Talwadekar, M., Shaw, E., Udipi, S., Kolthur-Seetharam, U., & Vaidya, A. D. B. (2021) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2021.04.007 · Cited by 15 · see citing works
Self-citationPicroside II as a Potential Anti-Inflammatory Agent
Ren, Y., Liu, Z., Wei, L., Wang, Y., Wang, Y., Guo, Y., & Ma, Z. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040499 · Cited by 2 · see citing works
“Pretreatment with picroside II ameliorated lipid accumulation induced by hepatic steatosis [105].”
- Authors
- Dhami-Shah, H., Vaidya, R., Udipi, S., Raghavan, S., Abhijit, S., Mohan, V., Balasubramanyam, M., & Vaidya, A.
- Affiliations
- Shreemati Nathibai Damodar Thackersey Women's University (IN)
- Madras Diabetes Research Foundation (IN)
- Corresponding author
- Dhami-Shah, Hiteshi
- ORCID
- Venue
- Clinical and Molecular Hepatology
- Published
- 2018-03-25
- Volume
- 24
- Issue
- 1
- Pages
- 77-87
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- PMC
- PMC5875197
- OpenAlex
- W2776703455
- Cited by
- 36
- References
- 4
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 2
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Molecular Hepatology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Department of Science & Technology, Government of India
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- picroside II, hepatic steatosis, fatty acid accumulation, fatty acid uptake, lipogenesis, SREBP1, stearoyl-CoA desaturase, phosphoenolpyruvate carboxykinase, gluconeogenesis, non-alcoholic fatty liver disease, HepG2 cells, Picrorhiza kurroa, silibinin
- MeSH terms
- Forkhead Box Protein O1, Animals, Cattle, Cinnamates, Fatty Acids, Gluconeogenesis, Humans, Serum Albumin, Bovine, Stearoyl-CoA Desaturase, Lipogenesis, Lipid Metabolism, Fatty Acid Transport Proteins, Sterol Regulatory Element Binding Protein 1, Hep G2 Cells, Iridoid Glucosides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
